TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine.
Fiche publication
Date publication
janvier 2009
Journal
Gastroenterologie clinique et biologique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr OUSSALAH Abderrahim, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Peyrin-Biroulet L, Oussalah A, Boucekkine T, Bigard MA
Lien Pubmed
Résumé
We conducted a survey of nonacademic gastroenterologists to evaluate the use of tumor necrosis factor (TNF) antagonists in inflammatory bowel disease (IBD).
Mots clés
Adalimumab, Antibodies, Monoclonal, therapeutic use, Antibodies, Monoclonal, Humanized, Azathioprine, therapeutic use, France, Gastrointestinal Agents, therapeutic use, Humans, Immunosuppressive Agents, therapeutic use, Inflammatory Bowel Diseases, drug therapy, Infliximab, Practice Patterns, Physicians', statistics & numerical data, Surveys and Questionnaires, Tumor Necrosis Factor-alpha, antagonists & inhibitors
Référence
Gastroenterol. Clin. Biol.. 2009 Jan;33(1 Pt 1):23-30